Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

41. Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study (Abstract)

Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy Using an NSAID for Other Pain Conditions: A Double-Blind Crossover Study To evaluate pregabalin's efficacy and safety versus placebo to reduce pain in patients with diabetic peripheral neuropathy (DPN) using a concomitant nonsteroidal anti-inflammatory drug.In a randomized, double-masked, 14-week, 2-period, crossover study, patients with painful DPN using a nonsteroidal anti-inflammatory drug for non-DPN-related pain received (...) 150 to 300 mg/d pregabalin or placebo (period 1); 14-day washout; then, the opposite therapy (period 2). Endpoints included weekly change in DPN pain score, sleep interference, adverse events, and patient-reported outcomes.Patients with similar baseline characteristics were randomized (period 1) to 1 of the 2 following possible sequences: pregabalin→placebo (n=154) or placebo→pregabalin (n=147). Results of the primary efficacy measure, mean weekly DPN pain at endpoint, showed no significant

2016 EvidenceUpdates Controlled trial quality: predicted high

42. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Full Text available with Trip Pro

Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with chronic pancreatic pain due to chronic pancreatitis is uncertain.To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE (...) difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes

2016 Cochrane

43. Preoperative use of pregabalin for acute pain in spine surgery: a meta-analysis of randomized controlled trials

Preoperative use of pregabalin for acute pain in spine surgery: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

44. Zonisamide, Levetiracetam, and Pregabalin use in the prophylactic treatment of episodic migraine: a systematic review with meta-analysis

Zonisamide, Levetiracetam, and Pregabalin use in the prophylactic treatment of episodic migraine: a systematic review with meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

45. Does the use of pregabalin and gabapentin increase the risk of dementia, pneumonia and unintentional falls? A systematic literature review

Does the use of pregabalin and gabapentin increase the risk of dementia, pneumonia and unintentional falls? A systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

46. Effectiveness of pregabalin in treatment of pruritus

Effectiveness of pregabalin in treatment of pruritus Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2016 PROSPERO

47. Pregabalin for prevention of chronic postoperative pain: systematic review with meta-analysis of randomized trials

Pregabalin for prevention of chronic postoperative pain: systematic review with meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

48. Benefits and harms of perioperative pregabalin treatment: a systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

Benefits and harms of perioperative pregabalin treatment: a systematic review of randomised clinical trials with meta-analyses and trial sequential analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO

49. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking (Abstract)

Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking This randomized, double-blind, placebo-controlled, multicenter, 2-period crossover study (two 6-week treatment periods separated by a 2-week washout period) evaluated the efficacy and safety of pregabalin (150 to 300 mg/d) for treatment of pain and pain on walking in patients with painful diabetic peripheral neuropathy (DPN) who experienced pain while walking.Co-primary (...) efficacy endpoints were: (1) mean pain score (last 7 daily pain diary scores, 0 to 10 numeric rating scale at end of each treatment period) and (2) DPN pain on walking (0 to 10 numeric rating scale immediately after walking 50 feet [15.2 m] on flat surface). Secondary endpoints included other pain parameters, patient-reported sleep, health-related quality of life, and safety measures.Two hundred three patients were treated (pregabalin, n=198; placebo, n=186), with no statistically significant treatment

2015 EvidenceUpdates Controlled trial quality: predicted high

50. Perioperative use of pregabalin for acute pain-a systematic review and meta-analysis (Abstract)

Perioperative use of pregabalin for acute pain-a systematic review and meta-analysis Evidence supporting postoperative pain management using pregabalin as an adjunct intervention across various surgical pain models is lacking. The objective of this systematic review was to evaluate "model-specific" comparative effectiveness and harms of pregabalin following a previously published systematic review protocol. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched (...) from inception through August 2013. Data were screened and single extraction with independent verification and dual risk of bias assessment was performed. Quality of evidence (QoE) was rated using the GRADE approach. Primary outcomes were pain relief at rest and on movement and reduction in postoperative analgesic consumption. A total of 1423 records were screened, and 43 studies were included. Perioperative pregabalin resulted in: 16% (95% confidence interval [CI], 9%-21%) reduction in analgesic

2015 EvidenceUpdates

51. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial (Abstract)

Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial Monotherapy with first-line drugs for neuropathic pain often fails to provide sufficient pain relief or has unacceptable side effects because of the need for high doses. The aim of this trial was to test whether the combination of imipramine and pregabalin in moderate doses would relieve pain more effectively than monotherapy with either of the drugs. This was a randomized, double-blind, placebo (...) -controlled, crossover, multicenter trial consisting of four 5-week treatment periods in patients with painful polyneuropathy. Treatment arms were imipramine 75 mg/d vs pregabalin 300 mg/d vs combination therapy vs placebo. Patients with polyneuropathy and symptoms for more than 6 months, age 20 to 85 years, pain intensity ≥4 on a 0- to 10-point numeric rating scale (NRS) and pain at least 4 days a week were included in the trial. A total of 262 patients were screened for participation, 73 patients were

2015 EvidenceUpdates Controlled trial quality: predicted high

52. The effect of gabapentin and pregabalin on acute postoperative pain in patients undergoing orthopaedic surgery

The effect of gabapentin and pregabalin on acute postoperative pain in patients undergoing orthopaedic surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

53. Pregabalin for restless legs syndrome: a systematic review

Pregabalin for restless legs syndrome: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

54. Pregabalin for preoperative anxiety: a systematic review

Pregabalin for preoperative anxiety: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

55. Pregabalin for pain in fibromyalgia in adults [Cochrane Protocol]

Pregabalin for pain in fibromyalgia in adults [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2015 PROSPERO

56. Pregabalin for decreasing pancreatic pain in chronic pancreatitis [Cochrane Protocol]

Pregabalin for decreasing pancreatic pain in chronic pancreatitis [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

57. Effect of gabapentin and pregabalin on chronic postoperative pain in patients following orthopaedic surgery

Effect of gabapentin and pregabalin on chronic postoperative pain in patients following orthopaedic surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2015 PROSPERO

58. A systematic review of perioperative pregabalin use for acute pain

A systematic review of perioperative pregabalin use for acute pain Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2015 PROSPERO

59. Pregabalin Zentiva

Pregabalin Zentiva 26 May 2015 EMA/CHMP/408316/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Zentiva International non-proprietary name: PREGABALIN Procedure No. EMEA/H/C/003900/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 (...) . Pharmacovigilance 18 2.6. Risk management plan 18 2.7. PSUR submission 22 2.8. Product information 22 2.8.1. User consultation 22 3. Benefit-risk balance 22 4. Recommendation 23 Pregabalin Zentiva Assessment report EMA/CHMP/408316/2015 Page 2/24 List of abbreviations AE adverse event API Active Pharmaceutical Ingredient AR Assessment Report ASM Active Substance Manufacturer ASMF Active Substance Master File = Drug Master File AUC Area Under the plasma Concentration AUC0-inf Area Under the plasma Concentration

2015 European Medicines Agency - EPARs

60. Pregabalin Accord

Pregabalin Accord 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 June 2015 EMA/CHMP/282380/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pregabalin Accord International non-proprietary name: pregabalin Procedure No. EMEA/H/C/004024/0000 Note Assessment report as adopted by the CHMP with all (...) (EMA) for Pregabalin Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 May 2014. The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which a Marketing Authorisation is or has been granted in the Union on the basis of a complete dossier

2015 European Medicines Agency - EPARs